Veradermics Posts $21.0M Q3 Loss, $798.4M Cash Funds Operations Into 2030
MANE has more than doubled off its 52-week low of $32.
Summary
Veradermics reported a $21.0 million third-quarter loss and $798.4 million in cash, which it says funds operations into 2030. G&A more than quintupled year over year as the company builds commercial infrastructure ahead of a potential VDPHL01 launch.
Key Events · Earnings and Guidance · MANE
-
Q3 Loss Flat, Cash Funds Runway to 2030
Net loss was $21.0 million for Q3 2026 versus $20.1 million a year earlier, while cash, cash equivalents and marketable securities reached $798.4 million as of September 30, 2026 — enough, per management, to fund operations into 2030 through multiple Phase 3 readouts and a potential commercial launch.
-
G&A More Than Quintuples on Launch Prep
General and administrative expense rose to $12.7 million from $2.3 million in Q3 2025, an increase of $10.5 million driven by payroll, $3.1 million of stock-based compensation, commercial readiness costs and professional fees. R&D fell $2.0 million to $16.1 million.
-
Clinical Program Already Public
The release restates positive Phase 3 Study '304' topline results announced in October 2026 and positive 12-month Study '302' Part B data announced November 9, 2026; no new efficacy or safety data is disclosed here.
-
Female Study '306' Readout Guided to 1H27
Enrollment in the registration-directed Phase 2/3 Study '306' in female pattern hair loss is complete, with topline data expected in the first half of 2027.
Analysis · MANE · Life Sciences
The balance sheet is the headline here: $798.4 million in cash and securities at September 30, 2026, which management says funds operations into 2030 through multiple Phase 3 readouts and a potential commercial launch. For a company burning roughly $21 million a quarter, that removes any near-term financing need, and it matters more than the loss itself, which was flat year over year. The expense mix is shifting toward launch preparation — G&A jumped to $12.7 million from $2.3 million a year ago, largely payroll, stock compensation and commercial readiness — while R&D actually fell $2.0 million. The clinical narrative is unchanged and already public: positive Phase 3 Study '304' data in October and positive 12-month Study '302' Part B data on November 9, with female Study '306' topline guided to the first half of 2027.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MANE was trading at $142.72 on NYSE in the Life Sciences sector, with a market capitalization of approximately $6B. The 52-week trading range was $32.00 to $146.58. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.